Lv1
98 积分 2024-11-27 加入
Strategies and challenges for the next generation of antibody–drug conjugates
1个月前
已完结
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
1个月前
已完结
Bayesian optimal interval designs for phase I clinical trials
1个月前
已完结
Tumor hypoxia and expression of c-met in cervical cancer
1个月前
已完结
Targeting MET in cancer: rationale and progress
1个月前
已完结
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial
1个月前
已完结
B7‐H3‐mediated tumor immunology: Friend or foe?
1个月前
已完结
Strategies and challenges for the next generation of antibody–drug conjugates
1个月前
已完结
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study
2个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
3个月前
已完结
皖公网安备34019202002308
